- Home
- XOMAP vs SBCF Comparison
XOMAP vs SBCF Comparison
Compare XOMAP & SBCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- SBCF
- Stock Information
- Founded
- XOMAP N/A
- SBCF 1926
- Country
- XOMAP United States
- SBCF United States
- Employees
- XOMAP 13
- SBCF N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- SBCF Major Banks
- Sector
- XOMAP Health Care
- SBCF Finance
- Exchange
- XOMAP Nasdaq
- SBCF Nasdaq
- Market Cap
- XOMAP N/A
- SBCF N/A
- IPO Year
- XOMAP N/A
- SBCF N/A
- Fundamental
- Price
- XOMAP $25.84
- SBCF $25.73
- Analyst Decision
- XOMAP
- SBCF Buy
- Analyst Count
- XOMAP 0
- SBCF 4
- Target Price
- XOMAP N/A
- SBCF $29.75
- AVG Volume (30 Days)
- XOMAP N/A
- SBCF 462.0K
- Earning Date
- XOMAP N/A
- SBCF 04-24-2025
- Dividend Yield
- XOMAP N/A
- SBCF 2.83%
- EPS Growth
- XOMAP N/A
- SBCF 15.45
- EPS
- XOMAP N/A
- SBCF 1.42
- Revenue
- XOMAP N/A
- SBCF $499,141,000.00
- Revenue This Year
- XOMAP N/A
- SBCF $19.15
- Revenue Next Year
- XOMAP N/A
- SBCF $9.92
- P/E Ratio
- XOMAP N/A
- SBCF $17.95
- Revenue Growth
- XOMAP N/A
- SBCF N/A
- 52 Week Low
- XOMAP N/A
- SBCF $21.90
- 52 Week High
- XOMAP N/A
- SBCF $31.68
- Technical
- Relative Strength Index (RSI)
- XOMAP 55.97
- SBCF 39.31
- Support Level
- XOMAP $25.73
- SBCF $25.75
- Resistance Level
- XOMAP $25.93
- SBCF $28.04
- Average True Range (ATR)
- XOMAP 0.08
- SBCF 0.90
- MACD
- XOMAP 0.03
- SBCF 0.03
- Stochastic Oscillator
- XOMAP 78.77
- SBCF 21.69
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.